Nadolol tablets are indicated for the long-term management of patients with angina pectoris and hypertension. The mechanism of the antihypertensive effects of beta-adrenergic receptor blocking agents has not been established. Nadolol is a nonselective beta blocker that competes with beta-adrenergic receptor agonists for available beta receptor sites. The exact antihypertensive mechanism of beta-adrenergic receptor blocking agents has not been established (2). It binds at beta-1 receptors in the heart and vascular smooth muscle, inhibiting the effects of epinephrine and norepinephrine and decreasing heart rate, cardiac output, and systolic and diastolic blood pressure (2, 4). This action is also thought to be the mechanism by which nadolol exerts its anti-anginal effects, thereby reducing the oxygen requirements of the heart and the velocity and extent of myocardial contraction (6). It also binds and blocks beta 2 receptors in bronchiole smooth muscle causing vasoconstriction. By binding beta 2 receptors in the kidney, nadolol inhibits the production of renin, thereby inhibiting angiotensin II and aldosterone production.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Nadolol, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.